Advertisement

Ceftriaxone Sodium Injection

[09 October 2014]

Products Affected - Description

Ceftriaxone sodium injection, Ben Venue Laboratories (formerly Bedford product)
250 mg vials, 10 count (NDC 55390-0309-10)
500 mg vials, 10 count (NDC 55390-0310-10)
1 gram vials, 10 count (NDC 55390-0311-10)
2 gram vials, 10 count (NDC 55390-0312-10)
10 gram vials, single count (NDC 55390-0316-01)
 
Ceftriaxone sodium injection, Hospira
250 mg vials, 10 count (NDC 00409-7337-01)
1 gram Add-vantage vials, 10 count (NDC 00409-7333-04)
2 gram vials, 10 count (NDC 00409-7335-03)
2 gram Add-vantage vials, 10 count (NDC 00409-7336-04)
 
Ceftriaxone sodium injection, Sagent
1 gram vials, 25 count (NDC 25021-0106-10)

Ceftriaxone sodium injection, Sandoz
2 gram vials, 10 count (NDC 00781-3209-95)
 
Ceftriaxone sodium injection, West-Ward
2 gram vials, 25 count (NDC 00143-9856-25)

Reason for the Shortage

  • Ben Venue stopped production in its plant in Bedford, Ohio and closed in July 2014.
  • Fresenius Kabi states the reason for the shortage is increased demand. 
  • Hospira states the reason for the shortage is manufacturing delay.
  • Sagent states the reason for the shortage is increased demand.
  • Sandoz cannot provide a reason for the shortage.
  • WG Critical Care states the reason for the shortage was increased demand.

Available Products

Ceftriaxone sodium injection, Apotex
250 mg vials, 10 count (NDC 60505-0750-04)
500 mg vials, 10 count (NDC 60505-0751-00)
2 gram vials, 10 count (NDC 60505-0753-04)
10 gram vials, single count (NDC 60505-0679-05)

Ceftriaxone sodium injection, BBraun
1 gram/50 mL premix, 24 count (NDC 00264-3153-11)
2 gram/50 mL premix, 24 count (NDC 00264-3155-11)

Ceftriaxone sodium injection, Baxter
1 gram/50 mL premix, 24 count (NDC 00338-5002-41)
2 gram/50 mL premix, 24 count (NDC 00338-5003-41)

Ceftriaxone sodium injection, Fresenius Kabi
250 mg vials, 25 count (NDC 63323-0344-10)
500 mg vials, 25 count (NDC 63323-0345-10)
1 gram vials, 25 count (NDC 63323-0346-10)
2 gram vials, 10 count (NDC 63323-0347-20)
10 gram vials, single count (NDC 63323-0348-61)

Ceftriaxone sodium injection, Hospira
500 mg vials, 10 count (NDC 00409-7338-01)
1 gram vials, 10 count (NDC 00409-7332-01)
10 gram vials, single count (NDC 00409-7334-10)

Ceftriaxone sodium injection, Lupin
250 mg vials, 10 count (NDC 68180-0611-10)
500 mg vials, 10 count (NDC 68180-0622-10)
1 gram vials, 10 count (NDC 68180-0633-10)
2 gram vials, 10 count (NDC 68180-0644-10)

Ceftriaxone sodium injection, Sagent
500 mg vials, 25 count (NDC 25021-0105-10)
2 gram vials, 25 count (NDC 25021-0107-20)
10 gram vial, single count (NDC 25021-0108-99)
 
Ceftriaxone sodium injection, Samson Medical Technologies
100 gram SmartPak bulk package (NDC 66288-6100-01)

Ceftriaxone sodium injection, Sandoz
250 mg vials, 10 count (NDC 00781-3206-95)
500 mg vials, 10 count (NDC 00781-3207-95)
1 gram vials, 10 count (NDC 00781-3208-95)
10 gram vials, single count (NDC 00781-3210-46)

Ceftriaxone sodium injection, WG Critical Care
500 mg vials, 25 count (NDC 44567-0700-25)
1 gram vials, 25 count (NDC 44567-0701-25)
2 gram vials, 25 count (NDC 44567-0702-25)
10 gram vial, single count (NDC 44567-0703-01)

Ceftriaxone sodium injection, West-Ward
250 mg vials, 25 count (NDC 00143-9859-25)
500 mg vials, 25 count (NDC 00143-9858-25)
1 gram vials, 25 count (NDC 00143-9857-25)

Estimated Resupply Dates

  • Hospira has ceftriaxone 250 mg vials, 1 gram ADD-Vantage vials, 2 gram vials, and 2 gram ADD-Vantage vials on back order with an estimated release date of October 2014.
  • Sagent has ceftriaxone 1 gram vials on back order with an estimated release date of November 2014.
  • Sandoz has ceftriaxone 2 gram vials on back order and the company estimates a release date in early-November 2014.
  • West-Ward has ceftriaxone 2 gram vials on back order and the company estimates a release date in late-October to early-November 2014.

Related Shortages

Updated

October 9, 2014; September 25, 2014; September 15, 2014; September 4, 2014; August 21, 2014; August 6, 2014; July 21, 2014; July 14, 2014; July 9, 2014; June 17, 2014; June 3, 2014; May 29, 2014; May 14, 2014; May 8, 2014; May 1, 2014, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement